ProNGF : Molecules to counter resistance mechanisms in breast cancer.
Description
Combinatorial therapy to circumvent resistance mechanisms in the case of breast cancers.The proposed technology can overcome the development of resistance to treatment in the case of breast cancer therapy failure (30% of cases) by blocking a newly identified tumor escape. This treatment strategy could be applied to other types of cancers: ENT, Prostate. A companion test was developed to orient and monitor treatment.
Benefits :
- Identification of a new co-receptor of TrkA and a new signaling pathway which is associated with a tumor escape route.
- The presence of this coreceptor is a poor prognostic factor (Correlation of coreceptor expression levels with the grade of cancer by the method of Duolink in Immunohistochemistry)
- Therapeutic strategy for chemo-resistant cancers (30% of cases) after treatment targeting tyrosine kinases (eg Lestaurtinib)
- Significant increase in life expectancy of the co-treated group (2 siRNAs) versus control groups (untreated, single treatment)
Sheet
Download the offer